DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Parnax Lab Ltd?

Parnax Lab Ltd has a price-to-earnings (PE) ratio of 14.2 in the Healthcare sector.

What is the market capitalisation of Parnax Lab Ltd?

Parnax Lab Ltd has a market capitalisation of approximately ₹167 crore.

Parnax Lab Ltd

PARNAXLABLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹96

₹182-112%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹167 Cr

P/E Ratio

14.20Cheap

P/B Ratio

1.76

EPS

₹10.26

Book Value

₹82.80

ROE

14.40%Average

ROCE

14.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.87Moderate

Face Value

₹10.00

52W High

₹182.00

52W Low

₹96.25

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

None moatHigh uncertainty

Fair value estimate

₹97

No recent traded price

BearFair valueBull

₹82₹97₹138

/100

Business quality — Solid

Growth 50Profitability 31Efficiency 30Valuation 73

Plain English

Our view

A steady, established business
Reasonably priced at 14× earnings

Strengths

Reasonably priced at 14× earnings
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

14% ROE fading to 13% over ~3 yrs, on ₹83 book

₹85

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹138

Analyst target

No analyst coverage

—

Blended fair value₹97

What the numbers say

Investment thesis

Bull case

Reasonably priced at 14× earnings
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

14.2Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

14.4%Average

Above 15% is considered healthy for Indian equities

ROCE

14.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.87Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹167 Cr

P/B

1.76

EPS

₹10.26

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 14.2×

Growth

Steady

+14% rev CAGR

Profitability

Healthy

14.4% ROE

Financial health

Comfortable

D/E 0.87

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+14.0%

+22.6%

10Y

+13.4%

Profit

+10.1%

—

10Y

+14.9%

EPS

+11.0%

—

10Y

+13.3%

Profile

Pros

Company is expected to give good quarter

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

72%

Promoter

Promoters

72.3%0.00

Public

23.3%-1.10

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

4.4%

Total shareholders

3,721-179 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.30%

Public23.27%

Others4.43%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]

Parnax Lab Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Parnax Lab Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare Parnax Lab Ltd with peers

Parnax Lab Ltd vs SUN PHARMACEUTICAL IND L Parnax Lab Ltd vs DIVI S LABORATORIES LTD Parnax Lab Ltd vs TORRENT PHARMACEUTICALS L Parnax Lab Ltd vs APOLLO HOSPITALS ENTER. L Parnax Lab Ltd vs ZYDUS LIFESCIENCES LTD Parnax Lab Ltd vs CIPLA LTD

Parnax Lab Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Parnax Lab Ltd valuation & research

Parnax Lab Ltd peers in Healthcare

Compare Parnax Lab Ltd with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions